Долгая жизнь с муковисцидозом. Коллектив авторов
R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998; 316: 1771-5.
24
Hamosh A, Rosenstein B, Nash E, et al. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med 1993; 329: 1308-13.
25
McKone EF, Emerson SS, Edwards KL, et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361: 1671-6.
26
McCloskey M, Redmond A, Hill A, et al. Clinical features associated with a delayed diagnosis of cystic fibrosis. Respiration 2000; 67: 402-7.
27
NickJA, Rodman DM. Manifestations of cystic fibrosis diagnosed in adulthood. Curr Opin Pulm Med 2005; 11:513-18.
28
Augarten A, Yahav Y, Szeinberg A, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849+ 10 kb C→T mutation. Lancet 1993; 342: 25–6.
29
McKone EF, Emerson SS, Edwards KL, et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 2003; 361: 1671-6.
30
Schechter MS. Non-genetic influences on cystic fibrosis lung disease: the role of sociodemographic characteristics, environmental exposures, and healthcare interventions. Semin Respir Crit Care Med 2003; 24: 639-52.
31
BlackmanS, HsuS, RitterS, etal. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009; 52: 1858-65.
32
Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302: 1076-83.
33
Drumm ML, Konstan MW, Schluchter MD, et al. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 2005; 353: 1443-53.
34
Farrell PM, Rosenstein BJ, White ТВ, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153: S4-S14.
35
DeBoeckK,Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627-35.
36
Augarten A, Yahav Y, Szeinberg A, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849+ 10 kb C→T mutation. Lancet 1993; 342: 25–6.
37
Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. N Engl J Med 1997; 337: 963-9.
38
Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/ multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros 2008; 7: 537-42.
39
Simmonds NJ, MacNeill SJ, Cullinan P, et al. Cystic fibrosis and survival to 40 years: a case-control study. Eur Respir J 2010; 36:1277-83.
40
Simmonds NJ, Cullinan R Hodson ME. Growing old with cystic fibrosis – the characteristics of long-term survivors of cystic fibrosis. Respir Med 2009; 103: 629-35.
41
Simmonds NJ, Cullinan R Hodson ME. Growing old with cystic fibrosis – the characteristics of long-term survivors of cystic fibrosis. Respir Med 2009; 103: 629-35.
42
Rodman DM, Polls JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 621-6.
43
Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/ multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros 2008; 7: 537-42.
44
Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/ multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros 2008; 7: 537-42.
45
Simmonds NJ, MacNeill SJ, Cullinan P, et al. Cystic fibrosis and survival to 40 years: a case-control study. Eur Respir J 2010; 36:1277-83.
46
Ramsey BW, Pepe MS, QuanJM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23–30.
47
Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-10.
48
OermannCM, Retsch BogartGZ, Quittner AL, et al. An 18 month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45: 1121-34.
49
Daniels T, Goodacre L, Sutton C, et al. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011; 140: 425-32.
50
Briesacher BA, Quittner AL, Saiman L, et al. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 2011; 11: 5.
51
Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009; 8: 91-6.
52
OermannCM, Retsch BogartGZ, Quittner AL, et al. An 18 month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45: 1121-34.
53
Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013; 68: 344-50.
54
Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011: 10:54–61.
55
Harrison M, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014; 13: 692-8.
56
DaviesJC, Geddes DM, Alton EW. Gene therapy for cystic fibrosis. J Gene Med 2001; 3: 409-17